CHRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CHRS is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has a mild short-term bounce, but the technical setup is still neutral-to-weak, earnings are imminent, and the company remains unprofitable. With no AI Stock Picker or SwingMax buy signal and no strong insider/hedge fund accumulation, I would not treat this as a clear buy today.
Price closed at 1.785, essentially at the pivot level of 1.786, which signals indecision rather than a confirmed uptrend. RSI_6 is 46.74, neutral and not oversold. MACD histogram is -0.00891, still below zero, though slightly improving as it contracts. Moving averages are converging, suggesting compression but not breakout confirmation. Key levels: support at 1.715 and 1.672, resistance at 1.856 and 1.899. Overall trend is sideways with a slight positive daily move, but not strong enough to call a clean long-term entry.
Upcoming Q1 2026 earnings on 2026-05-11 after market close could be an event-driven catalyst. The company’s revenue in 2025/Q4 grew 64.85% YoY, and gross margin improved to 68.27%, showing better operating efficiency. News also highlights LOQTORZI and ongoing oncology pipeline development, which supports the long-term story.
Net income was still deeply negative at -37.64M in 2025/Q4, and EPS remained negative at -0.31, so the business is not yet profitable. MACD remains negative, and the stock is trading near resistance rather than from a strong breakout base. Hedge funds and insiders are both neutral, which does not provide conviction. No recent congress trading data or notable politician/influencer buying activity was reported.
Latest reported quarter was 2025/Q4. Revenue increased to 12.75M, up 64.85% YoY, which is a strong top-line growth sign. Gross margin improved to 68.27%, also a positive trend. However, net income fell to -37.64M and EPS to -0.31, showing the company is still loss-making and not yet translating revenue growth into bottom-line improvement.
No analyst rating trend or price target change data was provided, so Wall Street sentiment cannot be confirmed from the dataset. Based on the available information, pros would point to revenue growth, improving gross margin, and pipeline potential. Cons would emphasize ongoing losses, lack of valuation support, neutral insider/hedge fund activity, and no strong signal from proprietary trading models.
